-

Nexus Pharmaceuticals Receives FDA Approval for Sterile Water for Injection, USP

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Sterile Water for Injection, USP in 10mL and 20mL Single-Dose Vials.

According to the FDA and the FD&C (Federal Food, Drug, and Cosmetic) Act, the product is considered bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Sterile Water for Injection USP, of Hospira, Inc. Furthermore, the FDA has granted CGT (competitive generic therapy) designation for the 20mL presentation of sterile water for injection.

“We are proud to be a force for change in the pharmaceutical industry, and we are grateful to the FDA for recognizing the importance of this critical-need product,” said Aman Ahmed, Director of Government Relations and International Sales at Nexus. “The approval of this product is an important step in continuing our efforts to alleviate drug shortages and bring pharmaceutical manufacturing back to the U.S.”

Nexus Pharmaceuticals’ Sterile Water for Injection will be available in cartons of 25 vials.

About Sterile Water for Injection, USP

Sterile Water for Injection, USP is a sterile, nonpyrogenic preparation of water for injection which contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection.

This parenteral preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.

About Nexus Pharmaceuticals LLC

Nexus Pharmaceuticals LLC., a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most.

Contacts

Grace Conroy
847-996-3790
gconroy@nexuspharma.net

Nexus Pharmaceuticals LLC


Release Summary
Nexus Pharmaceuticals announces U.S. Food and Drug Administration (FDA) approval for Sterile Water for Injection, USP.
Release Versions

Contacts

Grace Conroy
847-996-3790
gconroy@nexuspharma.net

Social Media Profiles
More News From Nexus Pharmaceuticals LLC

Nexus Pharmaceuticals Launches Tacrolimus Injection

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC announces the launch of Tacrolimus Injection, USP 5 mg/mL. This launch signifies the first and only Tacrolimus vial-format solution for healthcare providers and transplant centers to secure essential and cost-effective treatment options. Tacrolimus Injection, USP is a crucial immunosuppressant indicated for the prophylaxis of organ rejection in patients receiving liver or kidney transplants. “We are pleased to share the launch of N...

Nexus Wins Patent Litigation for Injectable Cyclophosphamide, Paving Way for Generic

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Wins Patent Litigation For Injectable Cyclophosphamide, Paving Way For Generic...

Nexus Pharmaceuticals Launches Methylene Blue Injection

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC proudly announces the launch of Methylene Blue Injection, USP. Methylene Blue Injection is indicated for the treatment of methemoglobinemia – a condition that affects the blood’s ability to carry oxygen. “The launch represents a vital addition to Nexus’ growing portfolio of life-saving and difficult-to-manufacture medications,” said Usman Ahmed, CEO of Nexus Pharmaceuticals. “Methylene Blue is a critical drug in emergency care, and...
Back to Newsroom